DETermination of the role of OXygen in suspected Acute Myocardial Infarction trial - 26/02/14
, Stefan K. James, MD, PhD d, Leif Svensson, MD, PhD a, Nils Witt, MD, PhD a, Mats Frick, MD, PhD a, Bertil Lindahl, MD, PhD d, Ollie Östlund, PhD d, Ulf Ekelund, MD, PhD e, David Erlinge, MD, PhD f, Johan Herlitz, MD, PhD c, Tomas Jernberg, MD, PhD bRésumé |
Background |
The use of supplemental oxygen in the setting of suspected acute myocardial infarction (AMI) is recommended in international treatment guidelines and established in prehospital and hospital clinical routine throughout the world. However, to date there is no conclusive evidence from adequately designed and powered trials supporting this practice. Existing data are conflicting and fail to clarify the role of supplemental oxygen in AMI.
Methods |
A total of 6,600 normoxemic (oxygen saturation [SpO2] ≥90%) patients with suspected AMI will be randomly assigned to either supplemental oxygen 6 L/min delivered by Oxymask (MedCore Sweden AB, Kista, Sweden) for 6 to 12 hours in the treatment group or room air in the control group. Patient inclusion and randomization will take place at first medical contact, either before hospital admission or at the emergency department. The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry will be used for online randomization, allowing inclusion of a broad population of all-comers. Follow-up will be carried out in nationwide health registries and Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies. The primary objective is to evaluate whether oxygen reduces 1-year all-cause mortality. Secondary end points include 30-day mortality, major adverse cardiac events, and health economy. Prespecified subgroups include patients with confirmed AMI and certain risk groups. In a 3-month pilot study, the study concept was found to be safe and feasible.
Conclusion |
The need to clarify the uncertainty of the role of supplemental oxygen therapy in the setting of suspected AMI is urgent. The DETO2X-AMI trial is designed and powered to address this important issue and may have a direct impact on future recommendations.
Le texte complet de cet article est disponible en PDF.Plan
| The study is registered at Clinical trial registration: ClinicalTrials.gov (NCT01787110). |
Vol 167 - N° 3
P. 322-328 - mars 2014 Retour au numéro
Article précédent
- Design and rationale of the TOTAL trial: A randomized trial of routine aspiration ThrOmbecTomy with percutaneous coronary intervention (PCI) versus PCI ALone in patients with ST-elevation myocardial infarction undergoing primary PCI
- Sanjit S. Jolly, John Cairns, Salim Yusuf, Brandi Meeks, Olga Shestakovska, Lehana Thabane, Kari Niemelä, Philippe Gabriel Steg, Olivier F. Bertrand, Sunil V. Rao, Alvaro Avezum, Warren J. Cantor, Samir B. Pancholy, Raul Moreno, Anthony Gershlick, Ravinay Bhindi, Robert C. Welsh, Asim N. Cheema, Shahar Lavi, Michael Rokoss, Vladimír Džavík
- Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation
- Menno V. Huisman, Gregory Y.H. Lip, Hans C. Diener, Sergio J. Dubner, Jonathan L. Halperin, Chang S. Ma, Kenneth J. Rothman, Christine Teutsch, Kristina Zint, Diana Ackermann, Andreas Clemens, Dorothee B. Bartels
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?